viability. Safety Toxicity and biological effects According to the United States Department of Agriculture iodomethane exhibits moderate to high acute toxicity for inhalation and ingestion. The Centers for Disease Control and Prevention (CDC) lists inhalation, skin absorption, ingestion, and eye contact as possible exposure routes with target organs of the eyes, skin, respiratory system, and the central nervous system. Symptoms may include eye irritation, nausea, vomiting, dizziness, ataxia, slurred speech, and dermatitis. In high dose acute toxicity, as may occur in industrial accidents, toxicity includes metabolic disturbance, renal failure, venous and arterial thrombosis and encephalopathy with seizures and coma, with a characteristic pattern of brain injury. Iodomethane has an for oral administration to rats 76 mg/kg, and in the liver it undergoes rapid conversion to S-methylglutathione. In its risk assessment of iodomethane, the U.S. EPA conducted an exhaustive scientific and medical literature search over the past 100 years for reported cases of human poisonings attributable to the compound. Citing the EPA as its source, the California Department of Pesticide Regulation concluded, "Over the past century, only 11 incidents of iodomethane poisoning have been reported in the published literature." (Hermouet, C. et al. 1996 & Appel, G.B. et al. 1975) "An updated literature search on May 30, 2007 for iodomethane poisoning produced only one additional case report." (Schwartz MD, et al. 2005). All but one were industrial—not agricultural—accidents, and the remaining case of poisoning was an apparent suicide. Iodomethane is routinely and regularly used in industrial processes as well as in most university and college chemistry departments for study and learning related to a variety of organic chemical reactions. Carcinogenicity in mammals It is considered a potential occupational carcinogen by the U.S. National Institute for Occupational Safety and Health (NIOSH), the U.S. Occupational Safety and Health Administration and the U.S. Centers for Disease Control and Prevention. The International Agency for Research on Cancer concluded based on studies performed after methyl iodide was Proposition 65 listed that: "Methyl iodide is not classifiable as to its carcinogenicity to humans (Group 3)." the Environmental Protection Agency classifies it as "not likely to be carcinogenic to humans in the absence of altered thyroid hormone homeostasis," i.e. it is a human carcinogen but only at doses large enough to disrupt thyroid function (via excess iodide). However this finding is disputed by the Pesticide Action Network which states that the EPA's cancer rating "appears to be based